Terlipressin infusion in catecholamine-resistant shock

Anaesthesia and Intensive Care

Volumn 31, Issue 5, 2003, Pages 560-564

  Jolley, D H ^a   De Keulenaer, B L ^a,b   Potter, A ^a   Stephen, D P ^a  

^a ROYAL DARWIN HOSPITAL   (Australia)

^b NONE   (Australia)

Author keywords

Shock: septic, refractory, cardiogenic, terlipressin, vasopressin

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADRENALIN; AMIODARONE; ANTIHYPERTENSIVE AGENT; CATECHOLAMINE; DOBUTAMINE; GENTAMICIN; HYDROCORTISONE; HYPERTENSIVE AGENT; ISOPHANE INSULIN; LOW MOLECULAR WEIGHT HEPARIN; MIDAZOLAM; MORPHINE; NORADRENALIN; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; SALBUTAMOL; SEDATIVE AGENT; TERLIPRESSIN; TETRACOSACTIDE; TIMENTIN; VASOPRESSIN DERIVATIVE;

ADULT; ARTICLE; BLOOD VESSEL TONE; BOLUS INJECTION; CARDIOGENIC SHOCK; CASE REPORT; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG INFUSION; DRUG WITHDRAWAL; FOOT DISEASE; HEART ATRIUM FIBRILLATION; HORMONE DEFICIENCY; HUMAN; HYPERTENSION; INTENSIVE CARE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RESPIRATORY TRACT DISEASE; TREATMENT OUTCOME;

EID: 0142062545     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0303100532     Document Type: Article

References (21)

1. Landry DW, Levin H, Gallant E et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997; 25:1279-1282.
2. Landry DW, Levin HR, Gallant EM et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125.
3. Tsuneyoshi I, Yamada H, Kakihana Y et al. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487-493.
4. O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock. Lancet 2002; 359:1209-1210.
5. Pedretti G, Elia G, Calzetti C et al. Octreotide versus terlpressin in acute variceal hemorrhage in liver cirrhosis. Emergency control and prevention of early rebleeding. Clin Investig 1994; 72: 653-659.
6. Silvain C, Carpentier S, Sautereau D et al. Terlipressin plus transdermal nitroglycerin vs octreotide in the control of acute bleeding from oesophageal varices: A multicenter randomized trial. Hepatology 1993; 18:61-65.
7. Garner WL, Rodriguez JL, Thomson PD et al. Control of hemorrhage during renal failure with triglycyl-lysine-vasopressin. Ann Plast Surg 1993; 31:78-81.
8. Onarheim H, Aanderud L, Rottingen JT et al. Triglycyl-lysine-vasopressin for reduction of blood loss during wound excision in patients with burns (letter). J Burn Care Rehabil 1994; 15: 392.
9. John EG, Schade SG, Spigos DG et al. Effectiveness of triglycyl vasopressin in persistent hematuria associated with sickle cell hemoglobin. Arch Intern Med 1980; 140:1589-1593.
10. Rundqvist E, Allen D, Larsson G. Comparison between lysine vasopressin and a long-acting analogue (N-alpha-triglycyl-lysine vasopressin) used as local hemostatic agents for conization. Acta Obstet Gynecol Scand 1998; 67:301-305.
11. Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33:43-48.
12. Eyraud D, Brabant S, Nathalie D et al. Treatment of intra-operative refractory hypotension with terlipressin in patients chronically treated with an antagonist of the renin-angiotensin system. Anesth Analg 1999; 88:980-984.
13. Holmes CL, Walley KR, Chittock DR et al. The effects of vasopressin on haemodynamics and renal function in severe shock: a case series. Intensive Care Med 2001; 27:1416-1421.
14. Heyndrickx GR, Boettcher DH, Vatner SF. Effects of angiotensin, vasopressin and methoxamine on cardiac function and blood flow distribution in conscious dogs. Am J Physiol 1976; 231:1579-1587.
15. László F, Karácsony G, Pávó I et al. Aggressive role of vasopressin in development of different gastric lesions in rats. Eur J Pharmacol 1994; 258:15-22.
16. Iwao T, Toyonaga A, Shigemori H et al. Vasopressin plus oxygen vs vasopressin alone in cirrhotic patients with portal-hypertensive gastropathy: effects on gastric mucosal haemodynamics and oxygenation. J Gastroenterol Hepatol 1996; 11: 216-222.
17. Boyle WA 3rd, Segel LD. Direct cardiac effects of vasopressin and their reversal by a vascular antagonist. Am J Physiol 1986; 251:H734-741.
18. Klasco RK [Editor]. DRUGDEX® System. Edition 115, Oct 2002. MICROMEDEX, Greenwood Village, CO, U.S.A.
19. Rittig S, Arentsen J, Sorensen K et al. The hemodynamic effects of trglycyl-lysin-vasopressin (Glypressin) in patients with parkinsonism and orthostatic hypotension. Mov Disord 1991; 6:21-28.
20. Auzinger GM, O'Callaghan PG, Harry RA et al. Terlipressin in the treatment of catecholamine resistant septic shock. Crit Care 2002; 6; 61 (abstr).
21. Asfar P, Pierrot M, Veal N et al. Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003; 31:215-220.